Skip to content

Released May 7, 2020, after the close

10-Q filed May 8, 2020, 38 days after period end · 0001564590-20-023566

Q1 2020 · 10-Q
Revenue$4.08M+5.0% vs Q1 2019−14.4% vs Q4 2019
Net Income-$26.66MN/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.76N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$27,694,000N/M
Operating Cash Flow-$25,218,000N/M
Free Cash Flowderived-$25,283,000N/M
Margins · derived
Operating margin-678.6%+50.8 pt vs Q1 2019
Net margin-653.1%+43.2 pt vs Q1 2019

What the release said

The release

Same quarter

MetricQ1 2020Q1 2019Q1 2018Q1 2017
Revenue$4.08M$3.89M$3.57M$684.00K
Net Income-$26.66M-$27.05M-$16.25M-$13.93M
EPS Diluted-$0.76-$1.05-$0.80-$810.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR